These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16968575)

  • 21. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
    Yu D; Murdoch SJ; Parikh SJ; Marcovina SM; Cobitz A; Chen H; Brunzell JD
    Diab Vasc Dis Res; 2006 Dec; 3(3):189-96. PubMed ID: 17160915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
    Chou HS; Palmer JP; Jones AR; Waterhouse B; Ferreira-Cornwell C; Krebs J; Goldstein BJ
    Diabetes Obes Metab; 2008 Aug; 10(8):626-37. PubMed ID: 17645558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Rosenstock J; Chou HS; Matthaei S; Seidel DK; Hamann A
    Diabetes Obes Metab; 2008 Sep; 10(10):862-73. PubMed ID: 18201206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.
    Wong TY; Szeto CC; Chow KM; Leung CB; Lam CW; Li PK
    Am J Kidney Dis; 2005 Oct; 46(4):713-9. PubMed ID: 16183427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
    Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
    Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
    Skov V; Cangemi C; Gram J; Christensen MM; Grodum E; Sørensen D; Argraves WS; Henriksen JE; Rasmussen LM
    Diabetes Care; 2014; 37(3):760-6. PubMed ID: 24135389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
    Stewart MW; Cirkel DT; Furuseth K; Donaldson J; Biswas N; Starkie MG; Phenekos C; Hamann A
    Diabet Med; 2006 Oct; 23(10):1069-78. PubMed ID: 16978370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
    Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
    Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
    Bakris GL; Ruilope LM; McMorn SO; Weston WM; Heise MA; Freed MI; Porter LE
    J Hypertens; 2006 Oct; 24(10):2047-55. PubMed ID: 16957566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
    Rosenstock J; Goldstein BJ; Vinik AI; O'neill MC; Porter LE; Heise MA; Kravitz B; Dirani RG; Freed MI;
    Diabetes Obes Metab; 2006 Jan; 8(1):49-57. PubMed ID: 16367882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
    Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
    Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.